Literature DB >> 17361127

Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.

S R Vlahakis1, G D Bren, A Algeciras-Schimnich, S A Trushin, D J Schnepple, A D Badley.   

Abstract

Human immunodeficiency virus (HIV) infection results in excessive apoptosis of infected and uninfected cells, mediated by host and viral factors present in plasma. As HIV protease inhibitors (PIs) have intrinsic antiapoptotic properties, we questioned whether HIV PIs could block HIV-induced CD4+ T-cell death independent of their effects on HIV replication. We demonstrate that HIV PIs block the death of CD4+ T cells induced by HIV glycoprotein 120 (gp120), Vpr, and Tat, as well as host signals Fas ligand, tumor necrosis factor, and tumor necrosis factor-related apoptosis-inducing ligand. Using gp120/CXCR4 as a model, we show that the HIV PIs specifically block mitochondrial apoptosis signaling. Furthermore, HIV PIs inhibit CD4+ T-cell death induced by viruses with high-level resistance to PIs (P<0.01) and apoptosis induced by serum of HIV patients with known resistance to HIV PIs (P=0.01). Together, these results show that HIV PIs block CD4+ T-cell death and have a beneficial effect on CD4+ T-cell survival despite PI resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361127     DOI: 10.1038/sj.clpt.6100140

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Head-to-head comparison of two first-line regimens and an NRTI-sparing regimen for initial therapy of HIV-1 infection: what should we start?

Authors:  David L Pitrak
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

2.  Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery.

Authors:  David L Pitrak; Richard M Novak; Randee Estes; Jean Tschampa; Christina D Abaya; Jeffrey Martinson; Kirsten Bradley; Allan R Tenorio; Alan L Landay
Journal:  AIDS Res Hum Retroviruses       Date:  2014-11-11       Impact factor: 2.205

3.  Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.

Authors:  Maile Y Karris; Sonia Jain; Vi Q Bowman; Gunter Rieg; Miguel Goicoechea; Michael P Dube; Shubha Kerkar; Carol Kemper; Catherine Diamond; Xiaoying Sun; Eric S Daar; Richard H Haubrich; Sheldon Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2016-06-01       Impact factor: 3.731

4.  Class-sparing regimens for initial treatment of HIV-1 infection.

Authors:  Sharon A Riddler; Richard Haubrich; A Gregory DiRienzo; Lynne Peeples; William G Powderly; Karin L Klingman; Kevin W Garren; Tania George; James F Rooney; Barbara Brizz; Umesh G Lalloo; Robert L Murphy; Susan Swindells; Diane Havlir; John W Mellors
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

Review 5.  Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis.

Authors:  H Garg; R Blumenthal
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

6.  A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial.

Authors:  K U Ulbricht; G M Behrens; M Stoll; B Salzberger; H Jessen; A B Jessen; B Kuhlmann; H Heiken; A Trein; R E Schmidt
Journal:  Open AIDS J       Date:  2011-04-22

7.  Choice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cells.

Authors:  Nathan W Cummins; Amy M Sainski; Sekar Natesampillai; Gary D Bren; Andrew D Badley
Journal:  Mol Cell Ther       Date:  2014-01-03

Review 8.  Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction.

Authors:  Reneé de Waal; Karen Cohen; Gary Maartens
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

Review 9.  The management of coronavirus infections with particular reference to SARS.

Authors:  Samson S Y Wong; Kwok-Yung Yuen
Journal:  J Antimicrob Chemother       Date:  2008-06-18       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.